FLEXJET
2.12.2020 10:34:40 CET | Business Wire | Press release
Flexjet Ltd. , offering travelers access to the world’s most luxurious fleet of private jets, accepted delivery of the first Praetor 600 aircraft in its European-based fleet, marking a significant milestone in the expansion of the company’s global business. Flexjet is the only shared-ownership/fractional provider of the Praetor 600 , part of a US$1.4 billion order for Embraer Executive Jets, a division of Embraer S.A. (NYSE: ERJ; BM&FBOVESPA: EMBR3), that was announced in October 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005564/en/
European Managing Director Marine Eugène leads the team headquartered at Flexjet House in the Mayfair neighbourhood in the west end of London. In addition, Flexjet has opened facilities including a European Tactical Control Centre in the United Kingdom to coordinate flight logistics, an aircraft maintenance facility in Milan and Flexjet House, where an experience center envelops current and prospective Flexjet shared aircraft Owners.
“Flexjet has taken the time to lay the groundwork to properly serve those entering the shared aircraft ownership market in Europe,” said Eugène. “Now that we have the infrastructure in place, we are growing our fleet with the addition of our new Praetor 600 aircraft. The Praetor 600 will form part of our Red Label by Flexjet offering, bringing to European-based travelers a unique combination of innovative technology, luxury and premium service. Our objective is to give Owners the ability to travel not just in North America but throughout Europe, Africa and the Middle East without leaving the safety and security of the Flexjet family.”
Currently, only 110 shared-ownership aircraft are providing more than 800,000 flight hours per year in Europe. In contrast, there are nearly 700 private aircraft supporting 1.2 million flight hours annually in the U.S. With its growing presence in Europe, Flexjet intends to meet the needs of a European market, underserved by existing flight providers, offering the personalized levels of service, consistency and attention to detail for which Flexjet is known.
The Praetor 600 will be part of the premium Red Label by Flexjet programme . The only offering of its kind, Red Label by Flexjet features flight crews assigned to a single, specific aircraft, custom cabin interiors and the youngest fleet in the industry as well as innovations established in response to the COVID-19 pandemic.
Having the youngest fleet in the industry is just one of the ways that Flexjet is meeting the industrywide commitment to achieving its sustainability goals by 2050. To meet that target, Flexjet Ltd. has implemented a standard sustainability offering that goes far beyond carbon-neutral. All Owners’ flights will be fully emissions-neutral, compensating for carbon dioxide (CO2) emissions and also other non-carbon dioxide warming pollutants in aviation, such as water vapor, aerosol sulphate and nitrous oxides. This comprehensive programme requires offsetting an additional 300 percent on top of standard CO2 emissions, a truly innovative first in the sector.
As the fleet launch customer for the Praetor 600, Flexjet will add it to its existing European-based fleet of Embraer Legacy 500s and 600s. Announced by Embraer in 2018, the super-midsize Praetor 600 seats nine passengers plus a cabin server and offers class-leading capabilities that make it ideal for both business and leisure use. Its exceptional short-field performance enables it to fly into small airports – including London City (EGLC) – which reduces transit time both to businesses in city centers and to remote vacation locations. The Praetor 600 is the farthest-flying super-midsize jet in the world and has a range of more than 4,000 miles, making it easy to fly without stops from Paris to New York or London to Dubai.
In addition, the Praetor 600 is equipped with unparalleled high-speed satellite Wi-Fi connectivity and an industry-first touchscreen Upper Tech Panel that puts flight information and cabin controls at the passenger’s fingertips. In the cockpit, the Praetor 600 is the first super-midsize jet with full fly-by-wire technology, which powers the Active Turbulence Reduction that not only makes every flight the smoothest but also the most efficient possible. One of the distinctive features of the Praetor 600 is the enlarged winglets, roughly six feet high, which contribute to the aircraft’s fuel efficiency.
The aircraft air quality management system is comprehensive, with the ability to move 100 percent fresh air through the cabin and an additional HEPA filter that further improves air quality by filtering out 99.97 percent of all particles including bacteria, viruses and fungi. The Praetor 600 also has a cabin altitude of 5,800 feet when the aircraft is cruising at 45,000 feet. This pressure level, combined with higher humidity levels, means travellers will feel less fatigued and more active during the flight and better refreshed on arrival.
“With private jet service recovering much faster than commercial aviation in the wake of the COVID-19 pandemic, it’s clear that travelers want to minimize their risk of exposure to the coronavirus, and private jets are a lower-risk way to fly in the COVID-19 era. That makes this the perfect time to bring both the versatile Praetor 600 and the Red Label experience to the European market,” said Flexjet Chief Executive Officer Michael Silvestro. “With Marine Eugène at the helm, we look forward to the continued growth and evolution of our European offering.”
Michael Amalfitano, President & CEO, Embraer Executive Jets , added “Flexjet is the fleet launch customer for the Praetor aircraft, continuing a two-decade-long partnership with Embraer. We are pleased that Flexjet is introducing the world’s most technologically advanced super-midsized aircraft, the Praetor 600, to the European shared ownership market and has the capabilities to thoroughly disrupt the business aviation market. We are confident that Flexjet passengers here in Europe will enjoy the ultimate experience in business and private aviation.”
Flexjet continues to be a leader in safety and the well-being of its Owners. Flexjet was the first private jet provider to decontaminate its cabins with anti-microbial treatments (MicroShield 360 in U.S.-based aircraft and Bacoban ® on EU-based aircraft). Each Flexjet cabin also is equipped with MedAire’s Universal Precaution Kit containing tools to help protect both passengers and crew from possible exposure. Every Flexjet pilot or crewmember wears masks and receives a mandatory temperature check pre-tour and a second while on duty. In addition, each crewmember remains in compliance with WHO-recommended guidelines for social distancing both on the ground and in the air.
About Flexjet
Flexjet first entered the fractional jet ownership market in 1995. Flexjet offers fractional jet ownership and leasing. Flexjet’s fractional aircraft programme is the first in the world to be recognized as achieving the Air Charter Safety Foundation’s Industry Audit Standard, is the first and only company to be honored with 21 FAA Diamond Awards for Excellence, upholds an ARG/US Platinum Safety Rating and is IS-BAO compliant at Level 2. Flexjet’s fractional programme fields an exclusive array of business aircraft—some of the youngest in the fractional jet industry, with an average age of approximately six years. In 2015, Flexjet introduced Red Label by Flexjet, which features the youngest fleet in the industry, flight crews dedicated to a single aircraft and the LXi Cabin Collection of interiors. To date there are more than 40 different interior designs across its fleet, which includes the Embraer Phenom 300, Legacy 450 and Praetor 500, Bombardier Challenger 350, the Gulfstream G450, G500, G650 and G700, and the Aerion AS2 supersonic business jets. Flexjet’s European fleet includes the Embraer Praetor 600, Legacy 500 and 600. Flexjet is a member of the Directional Aviation family of companies. For more details on innovative programmes and flexible offerings, visit www.flexjet.com or follow us on Twitter @Flexjet and on Instagram @FlexjetLLC .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005564/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
